Version 1
: Received: 3 August 2023 / Approved: 4 August 2023 / Online: 4 August 2023 (07:24:51 CEST)
How to cite:
Alam, M. N.; Almoyad, M. A. A.; Yu, J. Q.; Beale, P.; Proschogo, N.; Rupon, F. A.; Shahriar, M.; Huq, F. [Bis(quinoline)palladium (II) Chloride] as an Anticancer Drug Demonstrates Promising Activity on Its Own and in the Presence of 6-Shogaol. Preprints2023, 2023080381. https://doi.org/10.20944/preprints202308.0381.v1
Alam, M. N.; Almoyad, M. A. A.; Yu, J. Q.; Beale, P.; Proschogo, N.; Rupon, F. A.; Shahriar, M.; Huq, F. [Bis(quinoline)palladium (II) Chloride] as an Anticancer Drug Demonstrates Promising Activity on Its Own and in the Presence of 6-Shogaol. Preprints 2023, 2023080381. https://doi.org/10.20944/preprints202308.0381.v1
Alam, M. N.; Almoyad, M. A. A.; Yu, J. Q.; Beale, P.; Proschogo, N.; Rupon, F. A.; Shahriar, M.; Huq, F. [Bis(quinoline)palladium (II) Chloride] as an Anticancer Drug Demonstrates Promising Activity on Its Own and in the Presence of 6-Shogaol. Preprints2023, 2023080381. https://doi.org/10.20944/preprints202308.0381.v1
APA Style
Alam, M. N., Almoyad, M. A. A., Yu, J. Q., Beale, P., Proschogo, N., Rupon, F. A., Shahriar, M., & Huq, F. (2023). [Bis(quinoline)palladium (II) Chloride] as an Anticancer Drug Demonstrates Promising Activity on Its Own and in the Presence of 6-Shogaol. Preprints. https://doi.org/10.20944/preprints202308.0381.v1
Chicago/Turabian Style
Alam, M. N., Masum Shahriar and Fazlul Huq. 2023 "[Bis(quinoline)palladium (II) Chloride] as an Anticancer Drug Demonstrates Promising Activity on Its Own and in the Presence of 6-Shogaol" Preprints. https://doi.org/10.20944/preprints202308.0381.v1
Abstract
Synthesis and antitumour activity of a palladium compound, [Bis (quinoline) palladium (II) chloride] (coded as NH1) alone and in combination along with its proposed mechanism of action has been described in the present study. Antitumour activity has been performed in seven different cancer cell lines using colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. The investigated palladium compound demonstrated superiority over clinical standard cisplatin against drug resistant ovarian cancer cell lines. NH1 also demonstrates 4.4 times greater activity than cisplatin against breast cancer model. Binary sequenced combination study showed that NH1 in combination with curcumin is mostly additive to antagonistic. However, combination of NH1 with 6-shogaol demonstrated synergism depending on dose and sequence. Proteomic study revealed that changes in expression of 14 proteins were significantly associated with anticancer mechanism of NH1. In vivo anticancer activity of NH1 at a dose of 0.75 mg/kg was also evaluated using Erlich Ascites Carcinoma (EAC) cell lines in Swiss-albino mice model. Preliminary toxicity study in Swiss-albino mice proved that NH1 is comparatively less toxic at both of the administered doses, either 2.5 mg/kg or 5 mg/kg. However, cisplatin demonstrated significant toxicity at both of the administered doses. Biochemical investigations also supported that NH1 demonstrated lesser toxicity profile towards liver or kidney compared to clinical standard cisplatin.
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
